tbuckley/cabot-search huggingface dataset:
THU0546 Cross-Sectional Analysis of The Associations between Fibromyalgia and Other Chronic Co Morbidities
Authors: A. Lichtenstein, S. Tiosano, D. Comaneshter, A.D. Cohen, H. Amital
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> The Fibromyalgia syndrome (FMS) has been linked to chronic organic and psychiatric conditions, however large population studies that systematically investigated this claim are scarce (1). <h3>Objectives</h3> To evaluate the association of FMS with other common chronic diseases such as psychiatric, rheumatic, cardiovascular, pulmonary and malignant disorders. <h3>Methods</h3> Utilizing the database of “Clalit” health services, the largest health maintenance organization (HMO) in Israel serving roughly 4,000,000 members, we carried out a cross-sectional study. Fibromyalgia patients were compared to age- and sex- matched controls regarding the coexistence of other chronic diseases. Chi-square and t-tests were used for univariate analysis and a logistic regression model was used for multivariate analysis. <h3>Results</h3> The study included 14,296 patients with Fibromyalgia and 71,324 age- and sex- matched controls. The proportion of psychiatric disorders (anxiety, bipolar disease, depression, psychoses.) in patients with FMS was significantly higher compared with their proportion in controls (30.1% vs. 12.2% respectively, p&lt;0.001, OR =3.09, 95% CI: 2.96–3.22). The proportion of rheumatic disorders was also significantly higher in FMS patients compared to controls (10.8% and 3.15% respectively, p&lt;0.001, OR =3.73, 95% CI: 3.49–3.99). A multivariate logistic regression model demonstrated that FMS was significantly associated with psychiatric disorders and rheumatic diseases after controlling for confounders, including age, sex, socioeconomic status (SES) and BMI (psychiatric multivariate OR =3.17, p&lt;0.01 95% CI: 3.13–3.21; rheumatic multivariate OR =3.72, p&lt;0.01 95% CI: 3.65–3.79). In contrast, 1365 (1145 controls, 220 FMS) chronic heart failure patients and 1970 (1668 controls, 302 FMS) chronic renal failure patients were not found to be significantly associated with FMS (CHF: OR =0.96, p&lt;0.566 95% CI: 0.83–1.11; CRF: OR =0.90, p&lt;0.098 95% CI: 0.80–1.02). <h3>Conclusions</h3> Patients with the FMS have a greater proportion of psychiatric and rheumatic disorders than matched controls. Consequently, physicians treating patients with chronic illnesses in general and rheumatic or psychiatric conditions in particular, should be aware of this high co morbidity rate. <h3>References</h3> D. Buskila and H. Cohen, “Comorbidity of fibromyalgia and psychiatric disorders,” Current Science Inc, vol. 11, no. 5, pp. 333–338, Oct. 2007. <h3>Disclosure of Interest</h3> None declared
Cancer-Associated Deep Vein Thrombosis: The Role of Residual Vein Thrombosis for Assessing the Duration of Low Molecular Weight Heparin (the EXTENDED Cancer-DACUS)
Authors: Mariasanta Napolitano, Giorgia Saccullo, Simona Raso, Salvatrice Mancuso, Alessandra Casuccio, Sergio Siragusa
Journal: Blood (2014)
Intravascular Tissue Factor (TF) Is Predominantly Platelet-Associated during the Aplastic Phase of Hematopoietic Stem Cell Transplantation (HSCT).
Authors: Marketa Markova, Arne Slungaard, Omer Aras, Jessica L. Hysjulien, Janel Long, Arun Shet, Ronald R. Bach, Nigel S. Key
Journal: Blood (2004)
LTBK-01: PROSPECTIVE, MULTI-CENTER PHASE III TRIAL OF TUMOR TREATING FIELDS TOGETHER WITH TEMOZOLOMIDE COMPARED TO TEMOZOLOMIDE ALONE IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA
Authors: Roger Stupp, Ahmed Idbaih, David M. Steinberg, William Read, Steven Toms, Gene Barnett, Garth Nicholas, Chae-Yong Kim, Karen Fink, Andrea Salmaggi, Frank Lieberman, Jay Zhu, Lynne Taylor, Giuseppe Stragliotto, Andreas Hottinger, Eilon D. Kirson, Uri Weinberg, Yoram Palti, Monika E. Hegi, Zvi Ram
Journal: Neuro-Oncology (2016)

BACKGROUND:
Tumor Treating Fields (TTFields) is an established, frequency-tuned, anti-mitotic, physical treatment modality that acts in metaphase, anaphase and telophase. TTFields are delivered to the brain by a patient operated, portable medical device (Optune™, Novocure Ltd.). An international, multicenter, prospective, randomized phase 3 trial (EF-14) was initiated in 2009 to test the efficacy and safety of combining TTFields with temozlomide (TMZ) compared to TMZ alone following radiation therapy with adjuvant TMZ in patients with newly diagnosed GBM. Results of a protocol pre-specified successful interim analysis on the first 315 patients randomized has been reported (Stupp et al. JAMA 2015). Here we report the main outcomes of all 695 patients enrolled with a mature minimum follow-up of 18 month (median follow-up 36 months) for all patients (Range 19–80 months).
Porous Pt Nanoparticles with High Near‐Infrared Photothermal Conversion Efficiencies for Photothermal Therapy
Authors: Xiao‐Ming Zhu, Hong‐Ye Wan, Henglei Jia, Liang Liu, Jianfang Wang
Journal: Advanced Healthcare Materials (2016)

Plasmonic nanostructures are of potential in acting as a type of optical agents for cancer photothermal therapy. To effectively function as photothermal therapy agents, plasmonic nanostructures are strongly desired to have good biocompatibility and high photothermal conversion efficiencies. In this study, poly(diallyldimethylammonium chloride)‐coated porous Pt nanoparticles are synthesized for photothermal therapy. The Pt nanoparticles possess broadband near‐infrared light absorption in the range from 650 to 1200 nm, therefore allowing for selecting different laser wavelengths for photothermal therapy. The as‐prepared Pt nanoparticles exhibit remarkable photothermal conversion efficiencies under 809 and 980 nm laser irradiation. In vitro studies indicate that the Pt nanoparticles display good biocompatibility and high cellular uptake efficiencies through an endocytosis pathway. Photothermal heating using 808 nm laser irradiation (&gt;7.0 W cm −2 , 3 min) leads to notable cytotoxic effect, and more than 70% of cells are photothermally ablated after 3 min irradiation at 8.4 W cm −2 . Furthermore, simultaneous application of photothermal therapy synergistically enhances the cytotoxicity of an anti‐cancer drug doxorubicin. Therefore, the porous Pt nanoparticles have great potential as an attractive photothermal agent for cancer therapy.
ATPS-43POTENTIAL ROLE OF MOLECULAR GENETIC PROFILING TEST FOR THE TREATMENT OF PRIMARY AND SECONDARY CNS MALIGNANCIES
Authors: Lyndon Kim, James Evans, Kevin Judy, Christopher Farrell, David Andrews
Journal: Neuro-Oncology (2015)

BACKGROUND: Recurrent systemic malignancies with CNS metastases and recurrent malignant gliomas have a poor outcome. Once recurred and metastasized to CNS from systemic malignancies, prognosis is poor and most patients (pts) succumb to death within few weeks, even with treatment. The treatment options for recurrent malignant gliomas and rare CNS malignancies are also very limited due to lack of available drugs that are known to be effective. Most of these pts will not qualify for clinical trials. New novel treatment options are desperately needed. METHODS: 16 pts (5 pts: systemic malignancies with CNS involvement, 7 pts: glioblastomas, 4 pts: meningiomas) who were treated based on molecular genetic profile were evaluated. Molecular genetic profiling tests were performed from the tissue obtained from the previous surgery. Based on the test results after identifying the potential molecular target, each pt received the appropriate systemic therapy based on actionable mutations. Age, performance status, extent of CNS involvement and CNS penetration of the drug were carefully factored in choosing the appropriate drug for each pt. Tumor response was assessed with MRI after 1-2 cycles of treatment. RESULTS: All 5 pts with systemic malignancies and CNS involvement had a response. 2 PR (1 Squamous Ca and 1 Ovarian Ca, 3 SD (1 Squamous Ca, 1 Esthesioneuroblastoma, 1 Leiomyosarcoma). Tumor response was durable with 4 pts still alive and receiving Txs for >4 mo. 1 failed after 8 mo of therapy. 5/7 glioblastoma pts had SD for a minimum of 2 mo. 3 pts are currently undergoing Tx for >3mo. 4/4 meningiomas had SD for > 4 mo. CONCLUSION: Treatment of heterogeneously diverse primary and secondary CNS malignancies based on the molecular markers could be possible and thorough understanding of the key pathways and careful evaluation of each drug should be an integral part of treatment planning.
THU0115 Dependence of Arterial Pressure in Patients with Rheumatoid Arthritis on The Genotype of Bcl1 Polymorphism in Glucocorticoid Receptor Gene
Authors: V. Kmyta, O. Savchenko
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Objectives</h3> The objective is to study the incidence of arterial hypertension in patients with rheumatoid arthritis in regard to the genotype of BCL1 polymorphism in the glucocorticoid receptor gene. <h3>Methods</h3> 161 subjects with rheumatoid arthritis aged 40 years and older were investigated by means of instrumental, clinical and laboratory examinations. Rheumatoid arthritis was diagnosed according to ACR/EULAR Classification Criteria (2010). Arterial hypertension was diagnosed, when systolic arterial pressure was at or above 140 mmHg and diastolic arterial pressure – at or above 90 mmHg. Bcl1 polymorphism in exon 2 was defined by means of polymerase chain reaction with subsequent analysis of restriction fragment length polymorphism by I. Fleury et al. (venous blood was taken for the study). Statistical analysis was performed using SPSS–17 program. <h3>Results</h3> The patients with rheumatoid arthritis revealed the following: 10 patients had hypotension (6.2%); 60 subjects had normal arterial pressure (43.5%); 91 patients had arterial hypertension (56.5%). Of those having hypotension, 4 patients had C/C genotype (8.9%), 4 individuals presented with C/G genotype (5.1%) and 2 – with G/G genotype. Among the patients with normal pressure, 22 subjects were homozygous for the C allele (48.9%), 32 were heterozygous (40.5%) and 6 were homozygous for the G allele (16.2%). In the hypertensive group 19 individuals were homozygous for the C allele (42.2%), 43 were heterozygous (C/G allele) (54.4%) and 29 were homozygous for the pathologic G allele (78.4%). A significant difference was determined by Pearson9s chi-squared test (p=0.02) as for the genotype distribution in patients with rheumatoid arthritis and different levels of arterial pressure. Analysis of frequency of arterial pressure levels in these patients demonstrated an association between arterial hypertension and G/G genotype. <h3>Conclusions</h3> An association was found between the Bcl1 polymorphism in glucocorticoid receptor gene and arterial pressure level in patients with rheumatoid arthritis. A strong association between arterial hypertension and G/G genotype was proved. <h3>Disclosure of Interest</h3> None declared
PTH-101 Accuracy of Transient Elastography in Predicting Histological Fibrosis Severity in Treated Autoimmune Hepatitis?: Abstract PTH-101 Table 1
Authors: L Harrison, E McFarlane, A Dube, D Gleeson
Journal: Gut (2016)

<h3>Introduction</h3> The role of transient elastography (TE) or Fibroscan in assessing severity of liver fibrosis has been validated against liver biopsy in chronic hepatitis B and C and in NAFLD. There are few studies assessing its role in autoimmune hepatitis (AIH). Four preliminary studies have reported data on the role of Fibroscan in AIH. In these, most patients had recently started treatment and thus, still had active disease. Minimal data on transaminases was provided. We aimed to assess the accuracy of Fibroscan in predicting histological fibrosis severity in patients who had achieved biochemical remission (normal transaminases) and were undergoing follow-up liver biopsy to confirm histological remission as per our Unit’s clinical policy. <h3>Methods</h3> Between 1/12/13 and 31/12/15 36 same-day Fibroscan and liver biopsy were performed in 32 patients with AIH (1999 International Group criteria; 25 female, age 56 (17–78) years who had achieved biochemical remission (normal serum ALT and globulins) after 2.7 (2.1–24.9) years treatments. No patient had ascites, extrahepatic cholestasis or congestive cardiac failure based on clinical and laboratory evaluation. Fibroscan was performed in fasted patients using the Echosens machine (M or XL probe used as needed) by trained operators. We assessed how accurately the liver stiffness evaluation (LSE) score on Fibroscan could predict Ishak fibrosis stage on biopsy (assessed independently by AKD). <h3>Results</h3> The ALT was 21 (9–99), normal value &lt;33. 89% patients had normal serum ALT on the day. Ishak necroinflammatry score ≤3 (histological remission) was present in 12 biopsies (33%). Of the 36 Fibroscan’s carried out, 27 were valid. A valid scan defined by: ≥10 liver stiffness measurements, interquartile range (IQR)/median of &lt;0.30 and a success rate ≥ 60%. <h3>Conclusion</h3> In this study, Fibroscan showed good accuracy in excluding, but lower accuracy in predicting Ishak fibrosis stage of 4 or more. Accuracy was improved if a valid scan was obtained. Fibroscan was less accurate in predicting lower fibrosis stages. A combination of methods of assessing liver fibrosis may be necessary in some patients. <h3>Disclosure of Interest</h3> None Declared
P0295 : CD4+CD25+CD127low regulatory T cells play predominant anti-tumor suppressive role in hepatitis b virus associated hepatocellular carcinoma
Authors: S. Sharma, R. Khosla, P. David, A. Rastogi, A.K. Vyas, A. Bhardwaj, A. Sahney, R. Maiwall, G. Ramakrishna, S.K. Sarin, N. Trehanpati
Journal: Journal of Hepatology (2015)
Serum 2-Hydroxyglutarate Level Is a Prognostic Marker in Acute Myeloid Leukemia
Authors: Jing-Han Wang, Wen-Lian Chen, Tian-Lu Chen, Yong-Mei Zhu, Wei-Na Zhang, Yang Li, Song-Fang Wu, Yun-Ping Qiu, Ai-Hua Zhao, Jun-Min Li, Jian-qing Mi, Jie Jin, Yun-Gui Wang, He Huang, De-Pei Wu, Yan Li, Xiao-Jing Yan, Jin-Song Yan, Jian-Yong Li, Shuai Wang, Xiao-Jun Huang, Wei Jia, Zhu Chen, Sai-Juan Chen
Journal: Blood (2012)
AB1015 Mortality Rate According To Cause in Patients with Hemophagocytic Lymphohistiocytosis: A Meta-Analysis
Authors: K. Sheth, C.-L. Kuo, D. Modi, S. Nanavaty, C. Scola
Journal: Annals of the Rheumatic Diseases (2016)

<h3>Background</h3> Hemophagocytic lymphohistiocytosis (HLH) is a rare syndrome of excessive immune activation associated with high mortality. Early diagnosis and treatment can reduce mortality among these patients. <h3>Objectives</h3> To determine the rate of mortality independently and according to the cause in patients with HLH. <h3>Methods</h3> Pubmed database with the MeSH terms ("lymphohistiocytosis, hemophagocytic" [MeSH Terms] OR ("lymphohistiocytosis" [All Fields] AND "hemophagocytic" [All Fields]) OR "hemophagocytic lymphohistiocytosis" [All Fields] OR ("hemophagocytic" [All Fields] AND "lymphohistiocytosis" [All Fields])) AND cases [All Fields] were queried which yielded 466 results. Case series referenced from these studies were also studied. 74 studies were identified out of which the studies with a sample size smaller than 10 were excluded. 48 studies were kept with a total of 1983 patients. Meta analysis was performed to combine the mortality rates of all studies and studies of patients with the same cause. The results were presented in a Forest plot. Prior to the meta analysis, the heterogeneity test on mortalities was conducted to choose a fixed or random effects model. I<sup>2</sup>, a common heterogeneity measure, was reported with 25%, 50%, 75% suggesting low, moderate, and high heterogeneity. <h3>Results</h3> The combined mortality rate for all studies was 41.99% [95% confidence interval (CI) 36%&gt;49%]. In studies of patients with EBV infection (n=4), the combined mortality rate was 44% (95% CI 18%&gt;74%) whereas the mortality rate in studies with other infections (n=4) was 46% (95% CI 13–83%). The mortality rate in patients with hematological malignancy (n=8) was higher at 60% (95% CI 44%&gt;74%]. For studies of patients with autoimmune diseases (n=2) and in transplant (n=4) patients, the combined mortality rate was 11% (95% CI 5%&gt;21%) in patients with autoimmune disease and 38% (95% CI 27%&gt;51%) in transplant patients. I<sup>2</sup> for the mortalities of all studies and each cause was presented as follows: I<sup>2</sup>=0% (p=0.764) for autoimmune disease, I<sup>2</sup>=94.8% [89.6%; 97.4%] (p&lt;0.0001) for EBV infection, I<sup>2</sup>=75.2% [50%; 87.7%] (p=0.0002) for hematological malignancy, I<sup>2</sup>=75.2% [50%; 87.7%] (p=0.0002) for infection malignancy, I<sup>2</sup>=89.2% [75.1%; 95.3%] (p&lt;0.0001) for other infection, and I<sup>2</sup>=0% [0%; 52.1%] (p=0.811) for transplant. The heterogeneity test result remained significant but for the causes of autoimmune disease and transplant. <h3>Conclusions</h3> Based on our results, mortality is higher in patients with hematological malignancy compared to patients with other causes, whereas it is lower in patients with autoimmune disease. <h3>Disclosure of Interest</h3> None declared
Response to: Cryoglobulinemic vasculitis in the era of direct-acting antiviral drug
Authors: David Saadoun, Patrice Cacoub
Journal: Annals of the Rheumatic Diseases (2016)

We thank Moiseev et al for their interest in our work regarding sofosbuvir and ribavirin in hepatitis C virus (HCV)-associated mixed cryoglobulinemia vasculitis (VASCUVALDIC study)1 and to bring new elements for discussion.

Moiseev et al emphasise that treatment with immunomodulatory or immunosuppressive therapy (including rituximab) may have contributed to the impressive results of the VASCUVALDIC study. We have to stress that with the advent of new direct-acting antiviral (DAA) drugs (ie, sofosbuvir plus ribavirin), up to 87.5% of patients achieved complete clinical remission while only 17% of patients required the use of rituximab and glucocorticosteroids associated with antiviral therapy.1 In comparison, first-generation protease inhibitors …
Pregnancy outcomes in patients with type 1 diabetes in China: a retrospective study
Authors: Xueying Zheng, Jinhua Yan, Daizhi Yang, Sihui Luo, Dalong Zhu, Xingwu Ran, Jiajun Zhao, Xinhua Xiao, Xiaohui Guo, Tao Yang, Qin Huang, Zhiguang Zhou, Fang Liu, Ji Hu, Jing Lu, Jing Ma, Xinli Zhou, Fan Ping, Nan Gu, Mei Zhang, Wenwen Li, Yaling Yang, Chen Fang, Huixia Yang, Jianping Weng
Journal: The Lancet Diabetes & Endocrinology (2016)
Prolonged Sirolimus Administration after Matched Related and Unrelated Allogeneic Hematopoietic Cell Transplantation Is Associated with Decreased Risk for Moderate-Severe Chronic Graft Vs. Host Disease
Authors: Joseph Pidala, Jongphil Kim, Melissa Alsina, Ernesto Ayala, Brian C Betts, Hugo F Fernandez, Teresa Field, Mohamed A Kharfan-Dabaja, Frederick L Locke, Asmita Mishra, Taiga Nishihori, Jose L Ochoa-Bayona, Lia Perez, Marcie L Riches, Claudio Anasetti
Journal: Blood (2014)
Group effort in resuscitation teams
Authors: Rainer Spiegel
Journal: Behavioral and Brain Sciences (2016)

Abstract Baumeister and colleagues underline that individual identification and differentiation of selves are important characteristics for group performance. They name specialization, moral responsibility, and efficiency as vital components of well-functioning groups. In my commentary, I transfer their framework to the group effort within resuscitation teams to discuss for the first time how these components determine teamwork during resuscitation.
Oncolytic adenoviruses armed with TNFα and IL-2 enable successful adoptive T-cell therapy of solid tumors
Authors: S. Parviainen, R. Havunen, M. Siurala, S. Tähtinen, D. Saha, M. Vähä-Koskela, M. Behr, D. Nettelbeck, A. Ehrhardt, A. Hemminki
Journal: Annals of Oncology (2015)
Randomized Comparison of Allogeneic Versus Autologous Mesenchymal Stem Cells for Nonischemic Dilated Cardiomyopathy
Authors: Joshua M. Hare, Darcy L. DiFede, Angela C. Rieger, Victoria Florea, Ana M. Landin, Jill El-Khorazaty, Aisha Khan, Muzammil Mushtaq, Maureen H. Lowery, John J. Byrnes, Robert C. Hendel, Mauricio G. Cohen, Carlos E. Alfonso, Krystalenia Valasaki, Marietsy V. Pujol, Samuel Golpanian, Eduard Ghersin, Joel E. Fishman, Pradip Pattany, Samirah A. Gomes, Cindy Delgado, Roberto Miki, Fouad Abuzeid, Mayra Vidro-Casiano, Courtney Premer, Audrey Medina, Valeria Porras, Konstantinos E. Hatzistergos, Erica Anderson, Adam Mendizabal, Raul Mitrani, Alan W. Heldman
Journal: Journal of the American College of Cardiology (2016)

Although human mesenchymal stem cells (hMSCs) have been tested in ischemic cardiomyopathy, few studies exist in chronic nonischemic dilated cardiomyopathy (NIDCM).The authors conducted a randomized comparison of safety and efficacy of autologous (auto) versus allogeneic (allo) bone marrow-derived hMSCs in NIDCM.Thirty-seven patients were randomized to either allo- or auto-hMSCs in a 1:1 ratio. Patients were recruited between December 2011 and July 2015 at the University of Miami Hospital. Patients received hMSCs (100 million) by transendocardial stem cell injection in 10 left ventricular sites. Treated patients were evaluated at baseline, 30 days, and 3-, 6-, and 12-months for safety (serious adverse events [SAE]), and efficacy endpoints: ejection fraction, Minnesota Living with Heart Failure Questionnaire, 6-min walk test, major adverse cardiac events, and immune biomarkers.There were no 30-day treatment-emergent SAEs. Twelve-month SAE incidence was 28.2% with allo-hMSCs versus 63.5% with auto-hMSCs (p = 0.1004 for the comparison). One allo-hMSC patient developed an elevated (>80) donor-specific calculated panel reactive antibody level. The ejection fraction increased in allo-hMSC patients by 8.0 percentage points (p = 0.004) compared with 5.4 with auto-hMSCs (p = 0.116; allo vs. auto p = 0.4887). The 6-min walk test increased with allo-hMSCs by 37.0 m (p = 0.04), but not auto-hMSCs at 7.3 m (p = 0.71; auto vs. allo p = 0.0168). MLHFQ score decreased in allo-hMSC (p = 0.0022) and auto-hMSC patients (p = 0.463; auto vs. allo p = 0.172). The major adverse cardiac event rate was lower, too, in the allo group (p = 0.0186 vs. auto). Tumor necrosis factor-α decreased (p = 0.0001 for each), to a greater extent with allo-hMSCs versus auto-hMSCs at 6 months (p = 0.05).These findings demonstrated safety and clinically meaningful efficacy of allo-hMSC versus auto-hMSC in NIDCM patients. Pivotal trials of allo-hMSCs are warranted based on these results. (Percutaneous Stem Cell Injection Delivery Effects on Neomyogenesis in Dilated Cardiomyopathy [PoseidonDCM]; NCT01392625).